Market Cap 23.65B
Revenue (ttm) 3.81B
Net Income (ttm) -644.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 318.72
Profit Margin -16.92%
Debt to Equity Ratio 0.05
Volume 189,200
Avg Vol 468,388
Day's Range N/A - N/A
Shares Out 99.25M
Stochastic %K 82%
Beta 0.35
Analysts Strong Sell
Price Target $321.39

Company Profile

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 61 685 19 00
Address:
Aeschengraben 27, 21st Floor, Basel, Switzerland
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:46 PM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $311.73, showing bearish momentum as indicated by an RSI of 33.13, suggesting it is oversold. The stock is also below its 30-day moving average (MA30) of $333.31 and 50-day moving average (MA50) of $327.04, reinforcing a bearish trend. However, the proximity to the 60-day low of $299.50 indicates a potential reversal point. Directional Bias: The stock's current position near the lower end of its 60-day range suggests a possible bounce back. The ATR of 9.5 indicates volatility, providing opportunities for traders. Trade Plan: - Suggested Entry: $310.00 - Stop Loss: $295.00 (5% below entry) - Take Profit Targets: 1. $325.00 (5% ROI) 2. $340.00 (9.7% ROI) 3. $365.00 (17.2% ROI) This plan capitalizes on potential recovery while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
albiegf13
albiegf13 Dec. 23 at 1:46 PM
0 · Reply
albiegf13
albiegf13 Dec. 22 at 8:36 PM
0 · Reply
albiegf13
albiegf13 Dec. 20 at 4:13 PM
0 · Reply
1iquid
1iquid Dec. 20 at 1:45 PM
OptionWizards Tip (education only): Always define max loss before entering an options trade. $CMG $VMC $ONC Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:40 PM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $307.02, showing a significant bearish trend with an RSI of 25.84, indicating oversold conditions. The stock is below its moving averages (MA30 at 335.7 and MA50 at 328.05), suggesting continued downward pressure. However, the proximity to the 60D low of $299.5 indicates potential support. Directional Bias: Given the RSI and the current price near the 60D low, we anticipate a potential reversal or bounce back. The ATR of 10.42 suggests volatility, which could provide trading opportunities. Trade Plan: - Suggested Entry: $307.02 - Stop Loss: $295.00 (below the 60D low) - Take Profit Targets: 1. $320.00 (4.22% ROI) 2. $335.00 (9.10% ROI) 3. $360.00 (17.25% ROI) This plan allows for a strategic entry with favorable risk-reward ratios. Monitor the price action closely for signs of reversal. https://privateprofiteers.com
0 · Reply
prismmarketview
prismmarketview Dec. 18 at 6:13 PM
BeOne Medicines (NASDAQ: $ONC) has received FDA Fast Track designation for BGB‑B2033, a GPC3x4‑1BB bispecific antibody for adults with previously treated hepatocellular carcinoma, supporting accelerated development of the drug in an ongoing global Phase 1 trial both as monotherapy and in combination with PD‑1 inhibitor TEVIMBRA (tislelizumab).​ https://prismmarketview.com/beone-medicines-liver-cancer-therapy-receives-fda-fast-track-designation/
0 · Reply
albiegf13
albiegf13 Dec. 17 at 8:46 PM
2 · Reply
Quantumup
Quantumup Dec. 17 at 2:21 PM
RBC Capital reiterated $ONC Outperform-$408 and said, In-House Capabilities Can Drive Sustainable Near- and Long-Term Innovation $LLY $ABBV $AZN $VSTM BGNE ZLAB RBC Said: Yesterday we had the opportunity to take ONC mgmt on the road, with investor conversations focusing largely on the sustainability of ONC's development engine, as well as near-term competitive threats. We felt mgmt was confident that the company had built a true moat that enabled them to execute quickly and bring best-in-class molecules to the clinic and market — exemplified by Brukinsa, sonrotoclax, and '16673, which together round out their leadership in heme-onc with potential to offer treatment regimen for all slices of the market. We see reason to believe they can extend this strategy to solid tumors — which could constitute significant upside potential both to our and cons. ests. — and with the recent pullback in shares, we would be buyers into 2026 and data catalysts across both liquid and solid tumors.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:27 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $302.94, showing significant bearish momentum with an RSI of 28.13, indicating oversold conditions. The price is near the 60D low of $299.5, suggesting potential for a rebound. Directional Bias: Given the low RSI and proximity to the 60D low, there is a bullish bias for a potential reversal. However, the price is below both the 30-day MA (336.24) and 50-day MA (329.62), indicating resistance levels that need to be overcome. Trade Plan: - Suggested Entry: $303.50 (slightly above the last close to confirm upward momentum) - Stop Loss: $295.00 (below the 60D low to limit downside risk) - Take Profit Targets: 1. $320.00 (5.3% ROI) 2. $340.00 (12.0% ROI) 3. $355.00 (17.2% ROI) This plan aims for a minimum 17% ROI on the third target while managing risk effectively. Monitor closely for price action around the MA levels. https://privateprofiteers.com
0 · Reply
Latest News on ONC
BeOne Medicines Continues To Execute In Q3

Dec 4, 2025, 1:11 PM EST - 21 days ago

BeOne Medicines Continues To Execute In Q3


BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 3:16 PM EST - 7 weeks ago

BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript


BeOne Medicines to Present at Upcoming Investor Conferences

Oct 28, 2025, 6:01 AM EDT - 2 months ago

BeOne Medicines to Present at Upcoming Investor Conferences


BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 1:36 PM EDT - 5 months ago

BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 25 at 1:46 PM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $311.73, showing bearish momentum as indicated by an RSI of 33.13, suggesting it is oversold. The stock is also below its 30-day moving average (MA30) of $333.31 and 50-day moving average (MA50) of $327.04, reinforcing a bearish trend. However, the proximity to the 60-day low of $299.50 indicates a potential reversal point. Directional Bias: The stock's current position near the lower end of its 60-day range suggests a possible bounce back. The ATR of 9.5 indicates volatility, providing opportunities for traders. Trade Plan: - Suggested Entry: $310.00 - Stop Loss: $295.00 (5% below entry) - Take Profit Targets: 1. $325.00 (5% ROI) 2. $340.00 (9.7% ROI) 3. $365.00 (17.2% ROI) This plan capitalizes on potential recovery while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
albiegf13
albiegf13 Dec. 23 at 1:46 PM
0 · Reply
albiegf13
albiegf13 Dec. 22 at 8:36 PM
0 · Reply
albiegf13
albiegf13 Dec. 20 at 4:13 PM
0 · Reply
1iquid
1iquid Dec. 20 at 1:45 PM
OptionWizards Tip (education only): Always define max loss before entering an options trade. $CMG $VMC $ONC Not financial advice.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 3:40 PM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $307.02, showing a significant bearish trend with an RSI of 25.84, indicating oversold conditions. The stock is below its moving averages (MA30 at 335.7 and MA50 at 328.05), suggesting continued downward pressure. However, the proximity to the 60D low of $299.5 indicates potential support. Directional Bias: Given the RSI and the current price near the 60D low, we anticipate a potential reversal or bounce back. The ATR of 10.42 suggests volatility, which could provide trading opportunities. Trade Plan: - Suggested Entry: $307.02 - Stop Loss: $295.00 (below the 60D low) - Take Profit Targets: 1. $320.00 (4.22% ROI) 2. $335.00 (9.10% ROI) 3. $360.00 (17.25% ROI) This plan allows for a strategic entry with favorable risk-reward ratios. Monitor the price action closely for signs of reversal. https://privateprofiteers.com
0 · Reply
prismmarketview
prismmarketview Dec. 18 at 6:13 PM
BeOne Medicines (NASDAQ: $ONC) has received FDA Fast Track designation for BGB‑B2033, a GPC3x4‑1BB bispecific antibody for adults with previously treated hepatocellular carcinoma, supporting accelerated development of the drug in an ongoing global Phase 1 trial both as monotherapy and in combination with PD‑1 inhibitor TEVIMBRA (tislelizumab).​ https://prismmarketview.com/beone-medicines-liver-cancer-therapy-receives-fda-fast-track-designation/
0 · Reply
albiegf13
albiegf13 Dec. 17 at 8:46 PM
2 · Reply
Quantumup
Quantumup Dec. 17 at 2:21 PM
RBC Capital reiterated $ONC Outperform-$408 and said, In-House Capabilities Can Drive Sustainable Near- and Long-Term Innovation $LLY $ABBV $AZN $VSTM BGNE ZLAB RBC Said: Yesterday we had the opportunity to take ONC mgmt on the road, with investor conversations focusing largely on the sustainability of ONC's development engine, as well as near-term competitive threats. We felt mgmt was confident that the company had built a true moat that enabled them to execute quickly and bring best-in-class molecules to the clinic and market — exemplified by Brukinsa, sonrotoclax, and '16673, which together round out their leadership in heme-onc with potential to offer treatment regimen for all slices of the market. We see reason to believe they can extend this strategy to solid tumors — which could constitute significant upside potential both to our and cons. ests. — and with the recent pullback in shares, we would be buyers into 2026 and data catalysts across both liquid and solid tumors.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 2:27 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $302.94, showing significant bearish momentum with an RSI of 28.13, indicating oversold conditions. The price is near the 60D low of $299.5, suggesting potential for a rebound. Directional Bias: Given the low RSI and proximity to the 60D low, there is a bullish bias for a potential reversal. However, the price is below both the 30-day MA (336.24) and 50-day MA (329.62), indicating resistance levels that need to be overcome. Trade Plan: - Suggested Entry: $303.50 (slightly above the last close to confirm upward momentum) - Stop Loss: $295.00 (below the 60D low to limit downside risk) - Take Profit Targets: 1. $320.00 (5.3% ROI) 2. $340.00 (12.0% ROI) 3. $355.00 (17.2% ROI) This plan aims for a minimum 17% ROI on the third target while managing risk effectively. Monitor closely for price action around the MA levels. https://privateprofiteers.com
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Dec. 15 at 8:12 PM
📈 $HYFT: Chart Starting to Tell a New Story This morning’s earnings delivered record revenue growth, expanding margins, and major AI-pipeline progress, setting the tone for today’s strong price action. 🔥 Technical Highlights Powerful intraday move from $1.77 → $2.09 highs, confirming aggressive buyer interest 1️⃣ Healthy consolidation in the $1.85–$1.95 range 2️⃣Higher lows forming, showing steady accumulation on dips 3️⃣ Surging volume on the breakout, validating the move with real demand 4️⃣ Retesting the breakout zone as support, a constructive bullish pattern If $HYFT clears $2 with momentum, the next targets stack up at: $2.16 ➡️$2.31 ➡️ $2.50 ➡️ $2.75 ➡️ $2.92 ➡️ $3.26 With recent milestones and major catalysts ahead, HYFT is well positioned to tap into a fast growing multi-billion dollar AI-biotech market. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $CRSP $ABCL $ONC $ENTX
0 · Reply
albiegf13
albiegf13 Dec. 15 at 4:18 PM
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Dec. 15 at 1:05 PM
$HYFT: The Quiet Innovator That’s About to Get Loud 🔊 MindWalk Holdings is an AI driven biotech using its HYFT and LensAI platforms to disrupt a drug discovery market set to surge from $1.5B to $20B+ by 2030. Major Milestones 🔥 ➡Strategic rebrand + pivot into AI driven drug discovery ➡Revenue growth with narrowing losses ➡HYFT + LensAI gaining traction for speeding drug design Upcoming Catalysts ⚡ ➡Conference/earnings call today, any positive updates can spark fresh interest ➡Potential new platform updates ➡High-value partnership opportunities ➡Sector tailwinds from AI-biotech adoption Analyst Price Targets: 🎯Analysts sit around $3$5, suggesting notable upside. HYFT is helping shape the future of drug discovery, and the market is only beginning to catch on. Communicated Disclaimer : https://tinyurl.com/58pvrf5j Sector Peers: $CRSP $ABCL $ONC $ENTX
3 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 6:01 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $319.06, showing signs of potential recovery as the RSI is at 30.9, indicating oversold conditions. The price is near the 60D low of $306.0, suggesting a possible reversal. Directional Bias: With the RSI below 30, there is a bullish bias as the stock may be due for a rebound. The MA30 at $336.53 and MA50 at $331.11 indicate resistance levels, while the 60D high of $385.22 provides an upside target. Trade Plan: - Suggested Entry: $320.50 (slightly above the current close to confirm upward momentum) - Stop Loss: $306.00 (just below the 60D low) - Take Profit Targets: 1. $336.00 (1st target, approx. 4.8% ROI) 2. $350.00 (2nd target, approx. 9.4% ROI) 3. $375.00 (3rd target, approx. 17.5% ROI) This plan offers a favorable risk-reward ratio with a potential ROI exceeding 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 11 at 10:54 PM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $323.26, showing a bearish sentiment with an RSI of 32.31, indicating oversold conditions. The stock is below its 30-day moving average (MA30) of $336.25 and 50-day moving average (MA50) of $331.68, suggesting downward pressure. The recent 60-day high of $385.22 and low of $306.00 indicates potential for a rebound. Directional Bias: Given the oversold RSI and proximity to the 60-day low, there is a potential for a bullish reversal. The ATR of 12.3 suggests volatility, which can provide trading opportunities. Trade Plan: - Suggested Entry: $325.00 - Stop Loss: $306.00 (below the 60D low) - Take Profit Targets: 1. $340.00 (5% ROI) 2. $355.00 (9.8% ROI) 3. $380.00 (17.5% ROI) This plan aims for a minimum of 17% ROI on the third target, capitalizing on the potential rebound from oversold conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 10 at 2:58 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $318.69, significantly below its 60-day high of $385.22, indicating potential for recovery. The RSI at 22.96 suggests that the stock is oversold, which could lead to a bullish reversal. The moving averages (MA30 at 335.78 and MA50 at 332.28) indicate a bearish trend, but the extreme RSI level presents an opportunity for a bounce. Directional Bias: Given the oversold condition and proximity to the 60-day low of $306.00, we anticipate a bullish reversal. Trade Plan: - Suggested Entry: $320.00 - Stop Loss: $306.00 (below 60D low) - Take Profit Targets: 1. $335.00 (4.7% ROI) 2. $350.00 (9.2% ROI) 3. $373.00 (16.9% ROI) With these targets, we aim for a minimum of 17% ROI on the third target while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 8 at 10:45 PM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $328.38, significantly below its 60-day high of $385.22, indicating potential for a rebound. The RSI at 23.32 suggests the stock is oversold, which often precedes price reversals. The moving averages (MA30 at 335.73 and MA50 at 332.6) indicate a bearish trend but also highlight resistance levels to watch. Directional Bias: Given the oversold RSI and proximity to the 60-day low of $306.0, there is a bullish bias for a potential recovery towards the MA levels. Trade Plan: - Suggested Entry: $330.00 - Stop Loss: $306.00 (about 7.4% below entry) - Take Profit Targets: 1. $340.00 (3% gain) 2. $350.00 (6% gain) 3. $385.00 (16.6% gain) This trade plan aims for a minimum of 17% ROI on the third target while maintaining a manageable risk. Monitor closely for price action around the moving averages. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
albiegf13
albiegf13 Dec. 8 at 10:27 PM
0 · Reply
KissMyAngus02
KissMyAngus02 Dec. 8 at 8:51 PM
$IBRX $AMGN $ONC Lol. So you think theyre trying to affect a hostile bid? Or insider trading? Do tell. Lol
0 · Reply
albiegf13
albiegf13 Dec. 8 at 8:37 PM
$IBRX I believe someone is acumulating shares quietly and it ain't retail... I'm thinking $AMGN and $ONC...
4 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:46 AM
Actionable Trade Alert for $ONC: Market Context: $ONC is currently trading at $331.4, with an RSI of 29.42 indicating it is oversold. The stock is near its 60D low of $306.0, suggesting potential for a rebound. The MA30 at $334.72 and MA50 at $332.67 are close to the current price, indicating resistance levels. Directional Bias: Given the oversold RSI and proximity to the 60D low, we anticipate a bullish reversal. The ATR of 14.19 suggests volatility, which can provide trading opportunities. Trade Plan: - Suggested Entry: $331.4 - Stop Loss: $320.0 (3.9% below entry) - Take Profit Targets: - Target 1: $340.0 (2.6% gain) - Target 2: $350.0 (5.6% gain) - Target 3: $388.0 (17% gain) This plan allows for a favorable risk-reward ratio, aiming for a significant ROI on the third target. Monitor market conditions closely. https://privateprofiteers.com
0 · Reply
PrivateTrading
PrivateTrading Dec. 5 at 10:06 PM
$ONC I think that pirtobrutinib as a second line treatment will not do much if any harm to ONC. As a second line treatment, patients on Brukinsa would have to develop resistance then go to pirtobrutinib. If they develop resistance then they would be off Brukinsa anyway. One risk is if a doctor prescribes pirtobrutinib off-label as a first line treatment. But that action may not be best medical treatment because the risk would be if the CLL mutation did not work with the noncovalent pirtobrutinib then there would be no chance for a covalent treatment. The order of events has been to treat CLL/SLL with a covalent BTK inhibitor (Brukinsa, Calquence, Imbruvica) then if there is R/R to go to possibly a non-convalent (because it is reversible)
0 · Reply